Alumis (ALMS) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

ALMS Alumis

Watchlist

4.650
-0.020-0.43%

Close Feb 28 16:00 ET

4.650
0.0000.00%

Post 16:05 ET

252.99MMarket Cap-1.06P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
GlobeNewswireFeb 28 09:08 ET
Alumis Inc. to Present Data on A-005, a Novel TYK2 Inhibitor, at ACTRIMS Forum 2025
Quiver QuantitativeFeb 27 16:23 ET
Express News | Alumis Presents Additional Phase 1 Data at Actrims Forum 2025 Supporting Potential of a-005 as First-in-Class CNS Penetrant Tyk2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
ReutersFeb 27 16:15 ET
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
GlobeNewswireFeb 27 16:15 ET
Alumis Inc. Approves New Severance and Control Plan
TipRanksFeb 21 16:31 ET
Acelyrin Stock Jumps on Concentra Acquisition Interest
WSJFeb 21 09:16 ET

Comments

Jaguar8

Yesterday 22:09

NEWS

$Alumis (ALMS.US)$
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
Friday, 28th February at 9:08 am
– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis –
– Additional Phase 2 e-poster presentations to describe patient-reported outcomes,...

Jaguar8

Yesterday 05:15

NEWS

$Alumis (ALMS.US)$
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
Thursday, 27th February at 4:15 pm
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ: ALMS) ("Alumis" or the "Company"), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical ou...

Jaguar8

Feb 20 20:01

NEWS

$Alumis (ALMS.US)$ $Acelyrin (SLRN.US)$
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
Thursday, 20th February at 9:00 pm
LOS ANGELES, Feb. 20, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital...

Jaguar8

Feb 6 20:51

🟠Watchlist, FEBRUARY 7,2025, Friday. NFA- DrJag8 (I am not sure if I’ll be trading tomorrow)

NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...

104272950

Feb 6 18:00

drop?

$Alumis (ALMS.US)$ is this a drop that is expected to bounce back after merger confirmation?

ALMS Alumis

Trade Overview

Capital Trend

News

Comments

Trending Stocks